Japan’s largest drugmaker Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list. This is the biggest pharma acquisition of this year so far. Takeda was trying to close a deal for quiet a long time and the news came on tuesday when the official announced that both the companies have made an agreement. The final valuation of Dublin based shire is set at USD 62.1 billion, excluding debt according to the officials. Including shire’s debt the buyout is worth USD 80 billion making it biggest deal ever signed by a japanese pharmaceutical company. Takeda has a market value of around USD 33 billion and the deal has left the investors in fear of how to fund the acquisition. After this deal they will enter into the western markets opening new horizons for its growth.
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Global Top Players in Intraocular Lens (IOL) Market
- Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022
- Wearable Technology in Healthcare: Major Benefits and Trends
- World Population Day 2018
- How Metaverse is Set to Transform the Healthcare Dynamics?
Takeda buys Shire in a deal worth USD 62 billion
May 09, 2018 | Reading Time: < 1 minute
C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum’s Poziotinib; Orphan Drug Designation to Tenaya’s Gene Therapy; EC Approves Regeneron’s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer
C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...Find More
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL
Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...Find More
Genentech’s gantenerumab Fails in Phase III Trial; CHMP Recommends’ Dupixent; FDA Clears Imfinzi and Imjudo with chemotherapy; NICE Recommends Ipsen’s Cabometyx (cabozantinib); NICE Backs KEYTRUDA; NRG Announces £16 Million Series A Funding; FDA Backs AstraZeneca’s PT027
Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...Find More
Sign Up & Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.Join Up Now!
Sign up For Newsletters
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
ASCO Conference 2022
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.